8 October 2026
Save Our Sons connects with global neuromuscular community in Japan
Save Our Sons Duchenne Foundation joined more than 1,400 international clinicians, researchers and neuromuscular professionals at a major muscle disease congress in Japan.
From left: Save Our Sons Board members Miled Akle and Pierre BouAntoun, Foundation team member Deb Robbins and Duchenne Cardiac Specialist and Foundation Scientific Advisor Dr. Kan Hor.
Board members Miled Akle and Pierre BouAntoun, alongside team member Deb Robbins, represented the Foundation at the World Muscle Society Congress, held September 29 to October 3.
The international Congress brought together experts from across the neuromuscular field, with Duchenne and Becker muscular dystrophy among the conditions featured throughout the program.
Duchenne-specific sessions included “Decoding Duchenne”, which explored emerging therapeutic targets and meaningful clinical outcomes, alongside presentations on DMD clinical research and trials.
The program also included discussions on Duchenne treatment and disease management, including the care of older people living with Duchenne who are no longer ambulatory.
For Save Our Sons, the Congress provided an opportunity to reconnect with international clinicians and researchers, meet new specialists and strengthen relationships across the global Duchenne community.
Save Our Sons representatives Deb Robbins, Miled Akle, Pierre BouAntoun and Duchenne Cardiac Specialist Dr Kan Hor with Duchenne experts and international collaborators, including Paediatric Neurologist and DMD Specialist Brenda Wong and CureDuchenne Founder Debra Miller, at the World Muscle Society Congress in Japan.
Miled Akle said the Foundation’s attendance was particularly valuable as work continues to bring leading international experts together for the International Symposium 2.0.
“It was non-stop meeting new faces and creating new relationships,” Mr Akle said.
“We were able to reconnect with key stakeholders from around the world and meet doctors who might be interested in being part of next year’s symposium.”
The Foundation also met with pharmaceutical companies developing muscle therapies and discussed developments in the Duchenne treatment landscape, including therapies progressing through regulatory processes overseas.
As planning for International Symposium 2.0 continues, Save Our Sons is working to bring together leading clinicians, researchers and other experts from around the world to advance collaboration and improve the future of Duchenne care.
The World Muscle Society Congress provided an important opportunity to build relationships that will support Save Our Sons’ ongoing efforts to improve the future of Duchenne care.